5-HT1B receptor

Target id: 2

Nomenclature: 5-HT1B receptor

Family: 5-Hydroxytryptamine receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates.  » Email us

   GtoImmuPdb view: OFF :     5-HT1B receptor has curated GtoImmuPdb data

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 390 6q13 HTR1B 5-hydroxytryptamine receptor 1B 18,24,46,56,85
Mouse 7 386 9 E1 Htr1b 5-hydroxytryptamine (serotonin) receptor 1B 39
Rat 7 386 8q31 Htr1b 5-hydroxytryptamine receptor 1B 1,79
Previous and Unofficial Names
5-HT1B | 5-HT1DB | HTR1D2 | 5-HT1B serotonin receptor | serotonin receptor 1B | 5-HT1Dβ [56,85] | 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled
Database Links
Specialist databases
GPCRDB 5ht1b_human (Hs), 5ht1b_mouse (Mm), 5ht1b_rat (Rn)
Other databases
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
GenitoUrinary Development Molecular Anatomy Project
Human Protein Atlas
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of the chimeric protein of 5-HT1B-BRIL in complex with dihydroergotamine
PDB Id:  4IAQ
Ligand:  dihydroergotamine
Resolution:  2.8Å
Species:  Human
References:  80
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of the chimeric protein of 5-HT1B-BRIL in complex with ergotamine
PDB Id:  4IAR
Ligand:  ergotamine
Resolution:  2.7Å
Species:  Human
References:  80
Natural/Endogenous Ligands
5-hydroxytryptamine
Comments: Endogenous ligand tryptamine is a weak agonist

Download all structure-activity data for this target as a CSV file

Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[3H]N-methyl-AZ10419369 Hs Partial agonist 9.4 pKd 36
pKd 9.4 (Kd 3.7x10-10 M) [36]
[3H]8-OH-DPAT Hs Full agonist 8.9 pKd 51
pKd 8.9 [51]
[125I]GTI Rn Agonist 8.9 pKd 8-9
pKd 8.9 (Kd 1.3x10-9 M) [8-9]
[3H]alniditan Hs Full agonist 8.6 – 9.0 pKd 31
pKd 8.6 – 9.0 (Kd 2.51x10-9 – 1x10-9 M) [31]
[3H]eletriptan Hs Partial agonist 8.5 pKd 49
pKd 8.5 (Kd 3x10-9 M) [49]
[3H]sumatriptan Hs Partial agonist 8.0 pKd 49
pKd 8.0 (Kd 1.1x10-8 M) [49]
5-hydroxytryptamine Hs Full agonist 7.5 – 8.4 pKd 54,85
pKd 7.5 – 8.4 [54,85]
donitriptan Rn Partial agonist 9.7 pKi 25
pKi 9.7 [25]
oxymetazoline Hs Full agonist 9.5 pKi 29
pKi 9.5 [29]
GR 127935 Hs Partial agonist 9.0 – 9.8 pKi 16,27,60,68,84
pKi 9.0 – 9.8 [16,27,60,68,84]
donitriptan Hs Full agonist 9.4 pKi 25
pKi 9.4 [25]
L-694,247 Hs Full agonist 9.2 pKi 17
pKi 9.2 (Ki 6.3x10-10 M) [17]
SB 216641 Hs Partial agonist 9.0 pKi 60
pKi 9.0 [60]
alniditan Hs Full agonist 8.8 – 9.0 pKi 32
pKi 8.8 – 9.0 [32]
7-methoxy-1-naphthylpiperazine Hs Full agonist 8.7 pKi 27
pKi 8.7 [27]
CP94253 Hs Full agonist 8.7 pKi 28
pKi 8.7 (Ki 2x10-9 M) [28]
dihydroergotamine Hs Full agonist 8.0 – 9.2 pKi 32,54
pKi 8.0 – 9.2 [32,54]
CGS-12066 Hs Full agonist 8.1 – 8.7 pKi 17,85
pKi 8.1 – 8.7 [17,85]
ziprasidone Hs Full agonist 8.3 pKi 67
pKi 8.3 [67]
5-CT Hs Full agonist 7.7 – 8.8 pKi 54,85
pKi 7.7 – 8.8 [54,85]
5-hydroxytryptamine Hs Full agonist 7.4 – 9.0 pKi 12,50-51,68,84-85
pKi 7.4 – 9.0 [12,50-51,68,84-85]
5-(nonyloxy)-tryptamine Hs Full agonist 8.2 pKi 17
pKi 8.2 [17]
lysergol Hs Full agonist 7.5 – 8.9 pKi 54,85
pKi 7.5 – 8.9 [54,85]
5-CT Mm Full agonist 8.1 pKi 39
pKi 8.1 [39]
5-hydroxytryptamine Mm Full agonist 8.1 pKi 39
pKi 8.1 [39]
asenapine Hs Full agonist 8.1 pKi 67
pKi 8.1 [67]
RU 24969 Hs Full agonist 8.1 pKi 39
pKi 8.1 [39]
naratriptan Hs Partial agonist 8.1 pKi 49
pKi 8.1 [49]
eletriptan Hs Full agonist 8.0 pKi 49
pKi 8.0 (Ki 1x10-8 M) [49]
frovatriptan Hs Agonist 8.0 pKi 88
pKi 8.0 (Ki 1.03x10-8 M) [88]
BMS 181,101 Hs Partial agonist 7.6 – 8.1 pKi 50
pKi 7.6 – 8.1 [50]
1-naphthylpiperazine Hs Full agonist 7.7 – 7.9 pKi 27,54,85
pKi 7.7 – 7.9 [27,54,85]
lisuride Hs Partial agonist 7.7 pKi 43
pKi 7.7 [43]
zolmitriptan Hs Partial agonist 7.7 pKi 49
pKi 7.7 [49]
vortioxetine Hs Partial agonist 7.5 pKi 4
pKi 7.5 (Ki 3.3x10-8 M) [4]
5-MeOT Hs Full agonist 7.3 – 7.5 pKi 54,85
pKi 7.3 – 7.5 [54,85]
dipropyl-5-CT Hs Full agonist 7.4 pKi 85
pKi 7.4 [85]
sumatriptan Hs Partial agonist 6.5 – 8.1 pKi 17,32,44,49-50,54,85
pKi 6.5 – 8.1 (Ki 3.16x10-7 – 7.94x10-9 M) [17,32,44,49-50,54,85]
xanomeline Hs Full agonist 7.3 pKi 82
pKi 7.3 [82]
rizatriptan Hs Partial agonist 6.9 pKi 49
pKi 6.9 [49]
L-775,606 Hs Partial agonist 6.3 – 6.9 pKi 50
pKi 6.3 – 6.9 [50]
pergolide Hs Full agonist 6.6 pKi 43
pKi 6.6 [43]
terguride Hs Partial agonist 6.6 pKi 43
pKi 6.6 [43]
TFMPP Hs Full agonist 6.2 – 6.9 pKi 54,85
pKi 6.2 – 6.9 [54,85]
bromocriptine Hs Partial agonist 6.5 pKi 43
pKi 6.5 [43]
LY344864 Hs Full agonist 6.3 pKi 57
pKi 6.3 [57]
cabergoline Hs Full agonist 6.3 pKi 43
pKi 6.3 [43]
olanzapine Hs Full agonist 6.3 pKi 67
pKi 6.3 [67]
tryptamine Hs Full agonist 6.3 pKi 85
pKi 6.3 [85]
clozapine Hs Full agonist 6.2 pKi 67
pKi 6.2 [67]
BRL-15572 Hs Partial agonist 6.1 pKi 60
pKi 6.1 [60]
aripiprazole Hs Full agonist 6.1 pKi 70
pKi 6.1 [70]
2-methyl-5-HT Hs Full agonist 6.1 pKi 85
pKi 6.1 [85]
roxindole Hs Partial agonist 5.8 – 6.0 pKi 43,51
pKi 5.8 – 6.0 [43,51]
capeserod Hs Partial agonist 5.3 pKi 48
pKi 5.3 [48]
CP-122288 Hs Full agonist 7.6 pIC50 14
pIC50 7.6 [14]
L-772,405 Hs Full agonist 6.8 pIC50 64
pIC50 6.8 [64]
8-OH-DPAT Hs Full agonist 6.2 pIC50 14
pIC50 6.2 [14]
[11C]AZ10419369 Hs Partial agonist - - 78
[78]
View species-specific agonist tables
Agonist Comments
Frovatriptan is selective for 1B and 1D 5-HT receptor subtypes compared to the 1A subtype [88].
BRL-15572 can be used to distinguish between 5-HT1D and 5-HT1B receptors, being approximately 60-fold selective for the 1D subtype [60].
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
GR-55562 Hs Antagonist 7.4 pKB 22
pKB 7.4 [22]
[3H]GR 125,743 Hs Antagonist 8.6 – 9.2 pKd 17,87
pKd 8.6 – 9.2 (Kd 2.6x10-9 – 7.1x10-10 M) [17,87]
GR 127935 Hs Antagonist 9.2 pKi 17
pKi 9.2 [17]
5-OH-DPAT Mm Antagonist 8.4 pKi 39
pKi 8.4 [39]
SB 224289 Hs Inverse agonist 8.2 – 8.6 pKi 16,50,68
pKi 8.2 – 8.6 (Ki 6.31x10-9 – 2.51x10-9 M) [16,50,68]
ketanserin Mm Antagonist 8.3 pKi 39
pKi 8.3 [39]
spiperone Mm Antagonist 8.3 pKi 39
pKi 8.3 [39]
yohimbine Mm Antagonist 8.3 pKi 39
pKi 8.3 [39]
mianserin Mm Antagonist 8.3 pKi 39
pKi 8.3 [39]
SB236057 Hs Inverse agonist 8.2 pKi 41
pKi 8.2 (Ki 6.31x10-9 M) [41]
SB 272183 Hs Antagonist 8.1 pKi 83
pKi 8.1 [83]
(-)-pindolol Mm Antagonist 8.1 pKi 39
pKi 8.1 [39]
cyanopindolol Mm Antagonist 8.1 pKi 39
pKi 8.1 [39]
SB 649915 Hs Antagonist 8.0 pKi 81
pKi 8.0 [81]
methiothepin Hs Inverse agonist 7.1 – 8.5 pKi 17,50,54,84
pKi 7.1 – 8.5 [17,50,54,84]
GR-55562 Hs Antagonist 7.5 pKi 17
pKi 7.5 [17]
yohimbine Hs Antagonist 6.8 – 7.6 pKi 44,85
pKi 6.8 – 7.6 [44,85]
zotepine Hs Antagonist 7.2 pKi 67
pKi 7.2 [67]
metergoline Hs Antagonist 7.2 pKi 54
pKi 7.2 [54]
methysergide Hs Antagonist 6.6 – 7.6 pKi 54,85
pKi 6.6 – 7.6 [54,85]
sertindole Hs Antagonist 7.0 pKi 67
pKi 7.0 [67]
risperidone Hs Antagonist 6.6 – 7.3 pKi 31,67,69
pKi 6.6 – 7.3 [31,67,69]
rauwolscine Hs Antagonist 6.5 – 7.4 pKi 54,85
pKi 6.5 – 7.4 [54,85]
9-OH-risperidone Hs Antagonist 6.8 pKi 67
pKi 6.8 [67]
SB 714786 Hs Antagonist 6.7 pKi 81
pKi 6.7 [81]
(S)-flurocarazolol Hs Antagonist 6.5 pKi 62
pKi 6.5 [62]
pipamperone Hs Antagonist 6.2 pKi 67
pKi 6.2 [67]
(R)-flurocarazolol Hs Antagonist 6.1 pKi 62
pKi 6.1 [62]
S33084 Hs Antagonist 6.1 pKi 42
pKi 6.1 [42]
(+)-WAY 100135 Hs Antagonist 5.8 pKi 12
pKi 5.8 [12]
ocaperidone Hs Antagonist 6.9 – 7.2 pIC50 31
pIC50 6.9 – 7.2 [31]
ritanserin Hs Antagonist 6.0 – 6.5 pIC50 14,31
pIC50 6.0 – 6.5 [14,31]
ketanserin Hs Antagonist 5.2 – 5.4 pIC50 14,31
pIC50 5.2 – 5.4 [14,31]
View species-specific antagonist tables
Antagonist Comments
It is possible that radioligand [3H]N-methyl-AZ10419369 may have properties as a partial agonist at the 5-HT1B receptor [36].
Allosteric Modulators
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Affinity Units Reference
5-HT-moduline Hs Negative 11.9 pIC50 63
pIC50 11.9 [63]
Immuno Cell Type Associations
Immuno Cell Type:  T cells
Cell Ontology Term:  
Comment:  Involved in T cell proliferation.
References:  2
Immuno Cell Type:  Dendritic cells
Cell Ontology Term:   dendritic cell (CL:0000451)
Comment:  Involved in DC chemotaxis.
References:  2
Immuno Process Associations
Immuno Process:  Antigen presentation
Immuno Process ID:  3
Comment: 
GO Annotation:  Associated to GO processes, IEA only
GO Processes:  G-protein coupled receptor internalization (GO:0002031) IEA
References: 
Primary Transduction Mechanisms
Transducer Effector/Response
Gi/Go family Adenylate cyclase inhibition
References:  33,89
Tissue Distribution
Benign and malignant prostate tissue.
Species:  Human
Technique:  Western blotting.
References:  13
Brain: substantia nigra, globus pallidus > striatum > amygdala, hippocampus, septa region, hypothalamus.
Species:  Human
Technique:  Radioligand binding.
References:  76
Trigeminal ganglion.
Species:  Human
Technique:  immunocytochemistry.
References:  21
Cortical cerebral arteries (smooth muscle cell layer > endothelial cell layer).
Species:  Human
Technique:  immunocytochemistry.
References:  52
Coronary artery > atrium > ventricle, epicardium.
Species:  Human
Technique:  RT-PCR.
References:  53
Brain: substantia nigra, globus pallidus > caudate nucleus, putamen, nucleus accumbens, central gray, hippocampal formation > various cortical regions.
Species:  Human
Technique:  Radioligand binding.
References:  7
Brain: striatum, cortex, lateral geniculate nucleus, raphe nucleus.
Species:  Human
Technique:  in situ hybridisation.
References:  77
Suprachiasmatic nucleus.
Species:  Mouse
Technique:  Electron microscopic immunocytochemistry.
References:  6,58
Hypothalamus: magnocellular nuclei > supraoptic nucleus, paraventricular nucleus (dorsolateral) and accessory perifornical, circular and retrochiasmatic nuclei.
Species:  Rat
Technique:  Immunohistochemistry.
References:  37
Lumbar dorsal root ganglia, superior cervical ganglia, lumbar sympathetic ganglia.
Species:  Rat
Technique:  RT-PCR.
References:  59
Suprachiasmatic nucleus.
Species:  Rat
Technique:  Radioligand binding.
References:  38
Trigeminal ganglion.
Species:  Rat
Technique:  Immunohistochemistry.
References:  35
Thymus, peripheral blood lymphocytes, spleen, mitogen-activated spleen cells.
Species:  Rat
Technique:  RT-PCR.
References:  74
CNS: ventral pallidum, globus pallidus, dorsal subiculum, substantia nigra > caudate–putamen, entopeduncular nucleus, superficial gray layer of the superior colliculus, deep nuclei of the cerebellum > cerebral cortex, thalamus.
Species:  Rat
Technique:  immunocytochemistry.
References:  65
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of cAMP levels in mouse adrenal Y-1 cells transfected with the 5-HT1B receptor.
Species:  Human
Tissue:  Y-1 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  85
Measurement of cAMP levels in rat C6 glial cells transfected with the human 5-HT1B receptor.
Species:  Human
Tissue:  C6 glial cells.
Response measured:  Inhibition of cAMP accumulation.
References:  56
Measurement of cell growth ([3H]thymidine incorporation) of rat C6 glial cells transfected with the 5-HT1B receptor.
Species:  Human
Tissue:  C6 glial cells.
Response measured:  Cell proliferation.
References:  56
Measurement of cAMP levels in COS-7 cells transfected with the rat 5-HT1B receptor.
Species:  Rat
Tissue:  COS-7 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  1
Measurement of cAMP levels in NIH3T3 cells endogenously expressing the 5-HT1B receptor.
Species:  Mouse
Tissue:  NIH3T3 cell line.
Response measured:  Inhibition of cAMP accumulation.
References:  39
Physiological Functions
Vasoconstriction.
Species:  Human
Tissue:  Coronary artery.
References:  53
Vasocontriction.
Species:  Human
Tissue:  Cortical cerebral artery.
References:  52
Mediation of impulsivity and prefrontal cortex-dependent learning and memory.
Species:  Mouse
Tissue:  In vivo.
References:  55
Regulation of hippocampal functions.
Species:  Rat
Tissue:  In vivo.
References:  10
Inhibition of food intake.
Species:  Rat
Tissue:  In vivo.
References:  30
Presynaptic inhibition of GABA release onto GABAB receptors but not GABAA.
Species:  Rat
Tissue:  Dopamine-containing neurons of the midbrain.
References:  26
Inhibition of GABA release.
Species:  Rat
Tissue:  Globus pallidus.
References:  11
Relief from akinesia.
Species:  Rat
Tissue:  In vivo.
References:  11
Lowering of hippocampal excitatory synaptic transmission.
Species:  Rat
Tissue:  CA1 pyramidal neurons.
References:  45
Inhibition of glutamatergic synaptic transmission.
Species:  Rat
Tissue:  Hypoglossal motoneurons.
References:  72
Presynaptic inhibition of 5-HT (autoreceptor function), GABA and glutamate release (heteroreceptor function).
Species:  Mouse
Tissue:  Dorsal raphe, ventral midbrain and nucleus accumbens.
References:  47
Presynaptic decrease in retinal input to the circadian system.
Species:  Mouse
Tissue:  in vivo (retinal axons in the suprachiasmatic nucleus).
References:  58
Antinociception.
Species:  Mouse
Tissue:  Ventrolateral periaqueductal gray.
References:  5
Regulation of aggressive behaviour.
Species:  Mouse
Tissue:  In vivo.
References:  66
Presynaptic inhibition of 5-HT release.
Species:  Mouse
Tissue:  in vivo (frontal cortex and ventral hippocampus).
References:  75
Presynaptic inhibition of acetylcholine release.
Species:  Rat
Tissue:  Hippocampus.
References:  40
Presynaptic inhibition of dopamine release.
Species:  Rat
Tissue:  In vivo.
References:  3
Physiological Consequences of Altering Gene Expression
5-HT1B receptor knockout mice exhibit altered decision making abilities and response inhibition.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  55
5-HT1B receptor knockout mice exhibit facilitated reference memory and impaired delay-dependent working memory.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  86
Juvenile 5-HT1B receptor knockout mice exhibit reduced anxiety and hyperactivity, reduced sensitivity to 5-HT1A receptor activity and reduced 5-HT1A receptor abundance in some brain regions.
Species:  Mouse
Tissue: 
Technique:  Transgenesis.
References:  15
5-HT1B receptor knockout mice lack inhibition of 5-HT, GABA and glutamate release in the CNS.
Species:  Mouse
Tissue: 
Technique:  Transgenesis.
References:  47
5-HT1B knockout mice exhibit a reduced effect of cocaine on the induction of the immediate-early gene c-fos, commonly used as a molecular marker for neuronal activation. Indicates that this receptor subtype is involved in mediating the stimulatory effects of cocaine.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  34
5-HT1B knockout mice exhibit increased aggressive behaviour.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  66
5-HT1B receptor knockout mice exhibit no inhibition of 5-HT release in the frontal cortex and ventral hippocampus.
Species:  Mouse
Tissue: 
Technique:  Transgenesis.
References:  75
5-HT1B knockout mice exhibit altered monoamine metabolism in the CNS.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  3
5-HT1B receptor knockout mice exhibit elevated extracellular dopamine levels and dopamine release in the nucleus accumbens.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  71
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
MGI:96274  MGI:96285  MP:0000285 abnormal heart valve morphology PMID: 16380550 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0003313 abnormal locomotor activation PMID: 12798274 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas * 129S6/SvEvTac
MGI:96274  MP:0002803 abnormal operant conditional behavior PMID: 12742250 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0005006 abnormal osteoblast physiology PMID: 19041748 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0000057 abnormal osteogenesis PMID: 19041748 
Htr1b+|Htr1btm1Rhn Htr1btm1Rhn/Htr1b+
involves: 129S2/SvPas
MGI:96274  MP:0000057 abnormal osteogenesis PMID: 19041748 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0001463 abnormal spatial learning PMID: 12798274 
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
MGI:96274  MGI:96285  MP:0003141 cardiac fibrosis PMID: 16380550 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0001364 decreased anxiety-related response PMID: 10996411 
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
MGI:96274  MGI:96285  MP:0005140 decreased cardiac muscle contractility PMID: 16380550 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0001489 decreased startle reflex PMID: 11164514 
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
MGI:96274  MGI:96285  MP:0002795 dilated cardiomyopathy PMID: 16380550 
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
MGI:96274  MGI:96285  MP:0003958 heart valve hyperplasia PMID: 16380550 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0001354 increased aggression towards males PMID: 8091214 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0001260 increased body weight PMID: 11164514  11790410 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0005605 increased bone mass PMID: 19041748 
Htr1b+|Htr1btm1Rhn Htr1btm1Rhn/Htr1b+
involves: 129S2/SvPas
MGI:96274  MP:0005605 increased bone mass PMID: 19041748 
Htr1b+|Htr1btm1Rhn|Tg(Vil-cre)20Syr|Tph1+|Tph1tm1Kry Htr1btm1Rhn/Htr1b+,Tph1tm1Kry/Tph1+,Tg(Vil-cre)20Syr/0
involves: 129S2/SvPas * C57BL/6 * DBA/2
MGI:3053809  MGI:96274  MGI:98796  MP:0005605 increased bone mass PMID: 19041748 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0003911 increased drinking behavior PMID: 11790410 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0004988 increased osteoblast cell number PMID: 19041748 
Htr1b+|Htr1btm1Rhn Htr1btm1Rhn/Htr1b+
involves: 129S2/SvPas
MGI:96274  MP:0004988 increased osteoblast cell number PMID: 19041748 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0001147 small testis PMID: 11790410 
Biologically Significant Variants
Type:  Single nucleotide polymorphism
Species:  Human
Description:  861 G -> C polymorphism of the HTR1B gene: 861G allele linked to the development of attention deficit hyperactivity disorder (ADHD).
References:  20,61
Type:  Single nucleotide polymorphism
Species:  Human
Description:  861 G -> C polymorphism: 861C allele linked to the development of alcohol-dependence.
References:  19
Type:  Single nucleotide polymorphism
Species:  Human
Description:  861 G -> C polymorphism: 861C allele linked with substance abuse disorder and major depression.
References:  23
Type:  Single nucleotide polymorphism
Species:  Human
Description:  861 G -> C polymorphism: 861G allele linked to antisocial personality and conduct disorder in alcoholics.
References:  73

References

Show »

1. Adham N, Romanienko P, Hartig P, Weinshank RL, Branchek T. (1992) The rat 5-hydroxytryptamine1B receptor is the species homologue of the human 5-hydroxytryptamine1D beta receptor. Mol Pharmacol41: 1-7. [PMID:1732716]

2. Ahern GP. (2011) 5-HT and the immune system. Curr Opin Pharmacol11 (1): 29-33. [PMID:21393060]

3. Ase AR, Reader TA, Hen R, Riad M, Descarries L. (2000) Altered serotonin and dopamine metabolism in the CNS of serotonin 5-HT(1A) or 5-HT(1B) receptor knockout mice. J Neurochem75: 2415-2426. [PMID:11080193]

4. Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A et al.. (2011) Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J. Med. Chem.54 (9): 3206-21. [PMID:21486038]

5. Bartsch T, Knight YE, Goadsby PJ. (2004) Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol56: 371-381. [PMID:15349864]

6. Belenky MA, Pickard GE. (2001) Subcellular distribution of 5-HT(1B) and 5-HT(7) receptors in the mouse suprachiasmatic nucleus. J Comp Neurol432: 371-388. [PMID:11246214]

7. Bonaventure P, Schotte A, Cras P, Leysen JE. (1997) Autoradiographic mapping of 5-HT1B- and 5-HT1D receptors in human brain using [3H]alniditan, a new radioligand. Recept. Channels5 (3-4): 225-30. [PMID:9606727]

8. Boulenguez P, Segu L, Chauveau J, Morel A, Lanoir J, Delaage M. (1992) Biochemical and pharmacological characterization of serotonin-O-carboxymethylglycyl[125I]iodotyrosinamide, a new radioiodinated probe for 5-HT1B and 5-HT1D binding sites. J. Neurochem.58 (3): 951-9. [PMID:1738002]

9. Bruinvels AT, Palacios JM, Hoyer D. (1993) Autoradiographic characterisation and localisation of 5-HT1D compared to 5-HT1B binding sites in rat brain. Naunyn Schmiedebergs Arch. Pharmacol.347 (6): 569-82. [PMID:8361548]

10. Buhot MC, Naili S. (1995) Changes in exploratory activity following stimulation of hippocampal 5-HT1A and 5-HT1B receptors in the rat. Hippocampus5: 198-208. [PMID:7550615]

11. Chadha A, Sur C, Atack J, Duty S. (2000) The 5HT(1B) receptor agonist, CP-93129, inhibits [(3)H]-GABA release from rat globus pallidus slices and reverses akinesia following intrapallidal injection in the reserpine-treated rat. Br J Pharmacol130: 1927-1932. [PMID:10952684]

12. Davidson C, Ho M, Price GW, Jones BJ, Stamford JA. (1997) (+)-WAY 100135, a partial agonist, at native and recombinant 5-HT1B/1D receptors. Br J Pharmacol121: 737-742. [PMID:9208142]

13. Dizeyi N, Bjartell A, Nilsson E, Hansson J, Gadaleanu V, Cross N, Abrahamsson PA. (2004) Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate59: 328-336. [PMID:15042609]

14. Domenech T, Beleta J, Palacios JM. (1997) Characterization of human serotonin 1D and 1B receptors using [3H]-GR-125743, a novel radiolabelled serotonin 5HT1D/1B receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol356: 328-334. [PMID:9303569]

15. El-Khodor BF, Dimmler MH, Amara DA, Hofer M, Hen R, Brunner D. (2004) Juvenile 5HT(1B) receptor knockout mice exhibit reduced pharmacological sensitivity to 5HT(1A) receptor activation. Int J Dev Neurosci22: 405-413. [PMID:15380839]

16. Gaster LM, Blaney FE, Davies S, Duckworth DM, Ham P, Jenkins S, Jennings AJ, Joiner GF, King FD, Mulholland KR, Wyman PA, Hagan JJ, Hatcher J, Jones BJ, Middlemiss DN, Price GW, Riley G, Roberts C, Routledge C, Selkirk J, Slade PD. (1998) The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. J Med Chem41: 1218-1235. [PMID:9548813]

17. Granas C, Larhammar D. (1999) Identification of an amino acid residue important for binding of methiothepin and sumatriptan to the human 5-HT(1B) receptor. Eur J Pharmacol380: 171-181. [PMID:10513577]

18. Hamblin MW, Metcalf MA, McGuffin RW, Karpells S. (1992) Molecular cloning and functional characterization of a human 5-HT1B serotonin receptor: a homologue of the rat 5-HT1B receptor with 5-HT1D-like pharmacological specificity. Biochem Biophys Res Commun184: 752-759. [PMID:1315531]

19. Hasegawa Y, Higuchi S, Matsushita S, Miyaoka H. (2002) Association of a polymorphism of the serotonin 1B receptor gene and alcohol dependence with inactive aldehyde dehydrogenase-2. J Neural Transm109: 513-521. [PMID:11956970]

20. Hawi Z, Dring M, Kirley A, Foley D, Kent L, Craddock N, Asherson P, Curran S, Gould A, Richards S, Lawson D, Pay H, Turic D, Langley K, Owen M, O'Donovan M, Thapar A, Fitzgerald M, Gill M. (2002) Serotonergic system and attention deficit hyperactivity disorder (ADHD): a potential susceptibility locus at the 5-HT(1B) receptor gene in 273 nuclear families from a multi-centre sample. Mol Psychiatry7: 718-725. [PMID:12192616]

21. Hou M, Kanje M, Longmore J, Tajti J, Uddman R, Edvinsson L. (2001) 5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res909: 112-120. [PMID:11478927]

22. Hoyer D, Hannon JP, Martin GR. (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav.71 (4): 533-54. [PMID:11888546]

23. Huang YY, Oquendo MA, Friedman JM, Greenhill LL, Brodsky B, Malone KM, Khait V, Mann JJ. (2003) Substance abuse disorder and major depression are associated with the human 5-HT1B receptor gene (HTR1B) G861C polymorphism. Neuropsychopharmacology28: 163-169. [PMID:12496953]

24. Jin H, Oksenberg D, Ashkenazi A, Peroutka SJ, Duncan AM, Rozmahel R, Yang Y, Mengod G, Palacios JM, O'Dowd BF. (1992) Characterization of the human 5-hydroxytryptamine1B receptor. J Biol Chem267: 5735-5738. [PMID:1348246]

25. John GW, Pauwels PJ, Perez M, Halazy S, Le Grand B, Verscheure Y, Valentin JP, Palmier C, Wurch T, Chopin P, Marien M, Kleven MS, Koek W, Assie MB, Carilla-Durand E, Tarayre JP, Colpaert FC. (1999) F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine. J Pharmacol Exp Ther290: 83-95. [PMID:10381763]

26. Johnson SW, Mercuri NB, North RA. (1992) 5-hydroxytryptamine1B receptors block the GABAB synaptic potential in rat dopamine neurons. J Neurosci12: 2000-2006. [PMID:1578282]

27. Jorand-Lebrun C, Pauwels PJ, Palmier C, Moret C, Chopin P, Perez M, Marien M, Halazy S. (1997) 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem40: 3974-3978. [PMID:9397179]

28. Koe BK, Nielsen JA, Macor JE, Heym J. (1992) Biochemical and behavioural studies of the 5-HT1B receptor agonist, CP-94,253. Drug Development Research26: 241-250.

29. Law H, Dukat M, Teitler M, Lee DK, Mazzocco L, Kamboj R, Rampersad V, Prisinzano T, Glennon RA. (1998) Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation. J Med Chem41: 2243-2251. [PMID:9632357]

30. Lee MD, Kennett GA, Dourish CT, Clifton PG. (2002) 5-HT1B receptors modulate components of satiety in the rat: behavioural and pharmacological analyses of the selective serotonin1B agonist CP-94,253. Psychopharmacology (Berl)164: 49-60. [PMID:12373419]

31. Lesage AS, Wouters R, Van Gompel P, Heylen L, Vanhoenacker P, Haegeman G, Luyten WH, Leysen JE. (1998) Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol123: 1655-1665. [PMID:9605573]

32. Leysen JE, Gommeren W, Heylen L, Luyten WH, Van de Weyer I, Vanhoenacker P, Haegeman G, Schotte A, Van Gompel P, Wouters R, Lesage AS. (1996) Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol50: 1567-1580. [PMID:8967979]

33. Lin SL, Setya S, Johnson-Farley NN, Cowen DS. (2002) Differential coupling of 5-HT(1) receptors to G proteins of the G(i) family. Br J Pharmacol136: 1072-1078. [PMID:12145108]

34. Lucas JJ, Segu L, Hen R. (1997) 5-Hydroxytryptamine1B receptors modulate the effect of cocaine on c-fos expression: converging evidence using 5-hydroxytryptamine1B knockout mice and the 5-hydroxytryptamine1B/1D antagonist GR127935. Mol Pharmacol51: 755-763. [PMID:9145913]

35. Ma QP. (2001) Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport12: 1589-1591. [PMID:11409721]

36. Maier DL, Sobotka-Briner C, Ding M, Powell ME, Jiang Q, Hill G, Heys JR, Elmore CS, Pierson ME, Mrzljak L. (2009) [N-methyl-3H3]AZ10419369 binding to the 5-HT1B receptor: in vitro characterization and in vivo receptor occupancy. J. Pharmacol. Exp. Ther.330 (1): 342-51. [PMID:19401496]

37. Makarenko IG, Meguid MM, Ugrumov MV. (2000) Distribution of serotonin 5-hydroxytriptamine 1B (5-HT(1B)) receptors in the normal rat hypothalamus. Neurosci Lett.328: 155-159. [PMID:12133578]

38. Manrique C, Hery F, Faudon M, Francois-Bellan AM. (1999) Indirect evidence for an association of 5-HT(1B) binding sites with retinal and geniculate axon terminals in the rat suprachiasmatic nucleus. Synapse33: 314-323. [PMID:10421712]

39. Maroteaux L, Saudou F, Amlaiky N, Boschert U, Plassat JL, Hen R. (1992) Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers. Proc Natl Acad Sci U S A89: 3020-3024. [PMID:1557407]

40. Maura G, Raiteri M. (1986) Cholinergic terminals in rat hippocampus possess 5-HT1B receptors mediating inhibition of acetylcholine release. Eur J Pharmacol129: 333-337. [PMID:3780847]

41. Middlemiss DN, Göthert M, Schlicker E, Scott CM, Selkirk JV, Watson J, Gaster LM, Wyman P, Riley G, Price GW. (1999) SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor. Eur. J. Pharmacol.375 (1-3): 359-65. [PMID:10443589]

42. Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Dubuffet T, Lavielle G. (2000) S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther293: 1048-1062. [PMID:10869410]

43. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther303: 791-804. [PMID:12388666]

44. Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP, Cogé F, Galizzi JP, Boutin JA, Rivet JM, Dekeyne A, Gobert A. (2000) Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse35: 79-95. [PMID:10611634]

45. Mlinar B, Corradetti R. (2003) Endogenous 5-HT, released by MDMA through serotonin transporter- and secretory vesicle-dependent mechanisms, reduces hippocampal excitatory synaptic transmission by preferential activation of 5-HT1B receptors located on CA1 pyramidal neurons. Eur J Neurosci18: 1559-1571. [PMID:14511335]

46. Mochizuki D, Yuyama Y, Tsujita R, Komaki H, Sagai H. (1992) Cloning and expression of the human 5-HT1B-type receptor gene. Biochem Biophys Res Commun185: 517-523. [PMID:1610347]

47. Morikawa H, Manzoni OJ, Crabbe JC, Williams JT. (2000) Regulation of central synaptic transmission by 5-HT(1B) auto- and heteroreceptors. Mol Pharmacol58: 1271-1278. [PMID:11093763]

48. Moser PC, Bergis OE, Jegham S, Lochead A, Duconseille E, Terranova JP, Caille D, Berque-Bestel I, Lezoualc'h F, Fischmeister R, Dumuis A, Bockaert J, George P, Soubrie P, Scatton B. (2002) SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. J Pharmacol Exp Ther302: 731-741. [PMID:12130738]

49. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R. (1999) Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol368: 259-268. [PMID:10193663]

50. Newman-Tancredi A, Audinot V, Moreira C, Verriele L, Millan MJ. (2000) Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT(1B) receptor/G-protein stoichiometry. Mol Pharmacol58: 1042-1049. [PMID:11040052]

51. Newman-Tancredi A, Cussac D, Audinot V, Millan MJ. (1999) Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol359: 447-453. [PMID:10431754]

52. Nilsson T, Longmore J, Shaw D, Olesen IJ, Edvinsson L. (1999) Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br J Pharmacol128: 1133-1140. [PMID:10578124]

53. Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T, Edvinsson L. (1999) Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol372: 49-56. [PMID:10374714]

54. Parker EM, Izzarelli DG, Lewis-Higgins L, Palmer D, Shapiro RA. (1996) Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem67: 2096-2103. [PMID:8863519]

55. Pattij T, Broersen LM, van der Linde J, Groenink L, van der Gugten J, Maes RA, Olivier B. (2003) Operant learning and differential-reinforcement-of-low-rate 36-s responding in 5-HT1A and 5-HT1B receptor knockout mice. Behav Brain Res141: 137-145. [PMID:12742250]

56. Pauwels PJ, Wurch T, Amoureux MC, Palmier C, Colpaert FC. (1996) Stimulation of cloned human serotonin 5-HT1D beta receptor sites in stably transfected C6 glial cells promotes cell growth. J Neurochem66: 65-73. [PMID:8522991]

57. Phebus LA, Johnson KW, Zgombick JM, Gilbert PJ, Van Belle K, Mancuso V, Nelson DL, Calligaro DO, Kiefer AD, Branchek TA, Flaugh ME. (1997) Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci61: 2117-212. [PMID:9395253<